Neo-adjuvant therapy in breast cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Bafaloukos, D ^a  

^a Metropolitan Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; SEX HORMONE; TAMOXIFEN; THIOTEPA; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG TARGETING; EARLY CANCER; FOLLOW UP; HORMONAL THERAPY; HUMAN; IN VIVO STUDY; LYMPH NODE METASTASIS; MOLECULAR BIOLOGY; PARTIAL MASTECTOMY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 21344442673     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi704     Document Type: Article

References (47)

1. Halsted WS. The results of operations for the cure of cancer of the breast performed at The Johns Hopkins Hospital from June, 1889 to January, 1894. Johns Hopkins Hosp Rep 1894 1895; 4: 297-350.
2. Leroy d'Etoile JJJ. Une letter de M. Leroy d'Etoile sur l'extirpation des tumeurs cancereuses. Bull Acad Med 1867; 9: 454-458.
3. Paget J. Statistiek van den kanker (Cancer Statistics). Ned Weekl Geneesk 1852; 2(275): 410.
4. Christian MC, McCabe MS, Korn EL et al. The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. N Engl J Med 1995; 333: 1469-1474.
5. Haagensen CD, Bodian C. A personal experience with Kalsted's radical mastectomy. Ann Surg 1984; 199: 143-150.
6. Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539-1545.
7. Gardin G, Rosso R, Campora E et al. Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125 patients homogenously treated with a combined modality approach. Eur J Cancer 1995; 31A: 1428-1433.
8. Smith IE, Walsh G, Jones A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-429.
9. Smith IE, A'Hern RP, Howell A et al. Preoperative continuous infusional E Cis F (epirubicin, cisplatin and infusion 5FU) vs conventional AC chemotherapy for early breast cancer: A phase III multicentre randomised trial by the TOPIC Trial Group. Proc Am Soc Clin Oncol 2000; 19: 84A (Abstr 320).
10. Chollet P, Charier S, Brain E et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 33: 862-866.
11. Semiglazov VF, Topuzov EE, Bavli JL et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-Illa breast cancer. Ann Oncol 1994; 5: 591-595.
12. Mauriac L, Duran M, Avril A et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: Results of a randomised trial in a single centre. Ann Oncol 1991; 2: 347-354.
13. Scholl SM, Fourquet A, Asselain B et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial-S6. Eur J Cancer 1994; 30A: 645-652.
14. Powles TJ, Hickish TF, Makris A et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-552.
15. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: Nine year results from national Surgical Adjuvant Breast and Bowel project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
16. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
17. Mauriac L, Durand M, Avril A, Dilhuydy J-M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm. Ann Oncol 1991; 2: 347-354.
18. Dittrich C, Jakesz R, Gnant M. Preoperative paclitaxel (TOL) in the first-line therapy of patients with breast cancer T3/4, N0-3, M0, followed by surgery, CMF±tamoxifen and radiotherapy: Phase II trial. Proc Am Soc Clin Oncol 1997; 16: 166a (Abstr 581).
19. Volm M, Forment S, Symmans F et al. Neo-adjuvant paclitaxel for locally advanced breast cancer (LABC): Preliminary results. Proc Am Soc Clin Oncol 1998; 17: 181 (Abstr 695).
20. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17: 3412-3417.
21. Formenti SC, Spicer D, Skinner K et al. Paclitaxel alone and in combination with radiation therapy as neoadjuvant approach to locally advanced breast cancer (LABC): Clinical and pathological response. Proc Am Soc Clin Oncol 2001; 20: 39b (Abstr 1902).
22. Green MC, Buzdar AU, Smith T et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3 week (Q3wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21: 35a (Abstr 135).
23. Moliterni A, Tarenzi E, Capri G et al. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol 1997; 24 (Suppl 17): 10-14.
24. Pouillart P, Fumoleau P, Romieu G et al. Final results of a phase II, randomized parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/Taxol (paclitaxel) (AT) as neoadjuvant treatment of local regional breast cancer. Proc Am Soc Clin Oncol 1999; 18: 73a (Abstr 275).
25. Gianni L, Baselga J, Eiermann N et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST) on local regional disease. Proc Am Soc Clin Oncol 2002; 21: 34a (Abstr 132).
26. Alvarez A, Rodger J, Brosio C et al. Neoadjuvant chemotherapy for stage III breast cancer: Does the addition of paclitaxel to doxorubicin increase complete response-A single institution non-randomized study. Eur J Cancer 2002; 38 (Suppl 3): S73 (Abstr 134).
27. Romieu G, Tubiana-hulin M, Fumoleau P et al. A multicenter randomized phase II study of 4 or 6 cycles of Adriamycin/Taxol (paclitaxel) AT as neoadjuvant treatment of breast cancer (BC). Ann Oncol 2002; 13 (Suppl 5): 33-34. (Abstr 118).
28. Ezzat A, Rahal M, Bazarbashi S et al. High complete pathological response induced by circadian Taxol (T) and cisplatinum (P) in locally advanced breast cancer. Proc Am Soc Clin Oncol 1997; 16: 168a (Abstr 586).
29. Untch M, Konecny G, Ditsch N et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomized AGO study. Proc Am Soc Clin Oncol 2002; 21: 34a (Abstr 133).
30. Ezzat AA, Rahal M, Ajarim D et al. Dose-dense neoadjuvant sequential chemotherapy in the management of locally advanced breast cancer. A phase II study. Proc Am Soc Clin Oncol 2003; 22: 51 (Abstr 202).
31. Shenkier TN, O'Reilly S, Bryce C et al. A phase II trial of neoadjuvant doxorubicin/paclitaxel (AT) and cisplatin/paclitaxel (CT) in newly diagnosed patients with locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 2001; 20: (Abstr 1853).
32. Shenkier TN, O'Reilly S, Gelmon K et al. A phase II trial of two different sequences of neoadjuvant doxorubicin/paclitaxel (AT) and cisplatin/paclitaxel (CT) in patients with locally advanced breast cancer. Expression of markers over time. Breast Cancer Res Treat 2003; 82 (Suppl 1): S57 (Abstr 246).
33. Cristofanilli M, Fratarcangeli T, Frye D et al. Weekly high dose paclitaxel (HD-P) has significant antitumour activity in inflammatory breast cancer (IBC). Proc Am Soc Clin Oncol 2001; 20: 15b (Abstr 1807).
34. Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology (Huntingt) 1997; 11: 15-18.
35. Amat S, Bongnoux P, Penult-Llacca H et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast conservation rate. Br J Cancer 2003; 88: 1339-1345.
36. Von Minckwitz G, Costa SD, Eiermann W et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17: 1999-2005.
37. Von Minckwitz G, Costa SD, Raab G et al. Dose-dense doxorubicin, docetaxel and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase III study. J Clin Oncol 2001; 19: 3506-3515.
38. Von Minckwitz, Raab G, Blohmer JG et al. In vivo chemosensitivity adapted neoadjuvant chemotherapy (docetaxel-doxorubicin-cyclophosphamide followed by vinorelbine-capecitabine salvage therapy) in patients with primary breast cancer: Results of the GEPAR-TRIO randomised pilot study. Breast Cancer Res Treat 2003; 82 (Suppl 1): S54 (Abstr 236).
39. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from the National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
40. Hurley J, Doliny P, Silva O et al. Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 2002; 21: (Abstr 196).
41. Pegram MD, Pienkowski T, Northfelt DW et al. Results of two open label multicenter phase II studies of the synergistic, non-anthracycline based combination of docetaxel, platinum salt, and trastuzumab inHER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-769.
42. Brufsky AM, Cleary D, Fuchs C et al. First-line chemotherapy for metastatic breast cancer with docetaxel, carboplatin, and trastuzumab: A phase II trial. Proc Am Soc Clin Oncol 2003; 21: 50a (Abstr 71).
43. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527-1532.
44. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
45. Dowsett M, Smith IE, Ebbs Sr et al. Impact Trialists. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005 Jan 15; 11:951s-8s.
46. Catatiotti L, Buzdar A, Noguchi S, Bines J. Efficacy of preoperative Arimidex (anastrozole) compared with Tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. Eur J Cancer 2004; 2 (Suppl): 69.
47. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.